A randomized trial of adoptive immunotherapy with tumor‐infiltrating lymphocytes and interleukin‐2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer

• Published in: Cancer Vol. 78; no. 2; pp. 244 - 251
• Main Authors: Ratto, Giovanni B., Zino, Paolo, Mirabelli, Sandro, Minuti, Paolo, Aquilina, Riccardo, Fantino, Giovanni, Spessa, Elisabetta, Ponte, Marco, Bruzzi, Paolo, Melioli, Giovanni
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 15.07.1996
• Subjects: immunotherapy; interleukin‐2; lung cancer; surgery; tumor infiltrating lymphocyte

BACKGROUND A previous pilot study from our group suggested that: 1) adoptive immunotherapy (AI) with Tumor Infiltrating Lymphocytes (TIL) and recombinant Interleukin‐2 (rIL‐2) may be applied with safety in more than 80% of patients operated upon for stage III NSCLC, and 2) AI could be useful in pati...